Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News Analysis
Nature Reviews Drug Discovery 5, 987–988 (1 December 2006) | doi:10.1038/nrd2204
Panitumumab
&
Abstract
In September 2006, panitumumab (Vectibix; Amgen), a fully human antibody against the epidermal growth factor receptor (EGFR), was approved by the FDA for the treatment of patients with EGFR-expressing metastatic colorectal cancer with disease progression on or following fluoropyrimidine-, oxaliplatin- and irinotecan-containing chemotherapy regimens.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
